The global antipsychotic drugs market will expand by a 7 CAGR by 2027, due to the increasing prevalence of mental disorders such as schizophrenia, schizoaffective disorder, bipolar disorder, severe depression, psychotic symptoms of a personality disorder, and others, according to a report by DelveInsight. Also, the growing geriatric population base prone to mental disorders, the increased focus of governments and healthcare organizations on mental health, the increasing demand for long-acting injectables, and other factors will contribute to an increase in demand for antipsychotic drugs.
North America is leading the world in terms of both market share and R&D activity.The US’s players are focusing developing novel drugs to treat mental disorders indications with antipsychotic drugs, as well as various strategies to develop better drugs with fewer side effects.